Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | CDK1 | P06493 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | PDE5A | O76074 | 2/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.40 |
| ▸ | CDK2 | P24941 | 2/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 3/20 | 0.38 |
| ▸ | FLT1 | P17948 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | GRK2 | P25098 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1216376 | 0.87 | CDK1 (0.55) | TMIGD3HTR2CHTR2BCDK1SMN1; SMN2 | |
| SCHEMBL5828183 | 0.87 | CCNE2 (0.52) | TMIGD3HTR2CHTR2BCDK1PDE5A | |
| SCHEMBL20119384 | 0.85 | TMIGD3 (0.41) | TMIGD3HTR2CHTR2BCDK1SMN1; SMN2 | |
| SCHEMBL26784724 | 0.85 | CCNE2 (0.44) | TMIGD3HTR2CHTR2BCDK1PDE5A | |
| SCHEMBL28455889 | 0.84 | PDE2A (0.51) | TMIGD3HTR2CHTR2BCDK1APP | |
| SCHEMBL3852234 | 0.84 | KDM4C (0.49) | TMIGD3HTR2CHTR2BCDK1SMN1; SMN2 | |
| SCHEMBL3304345 | 0.83 | KCNH3 (0.39) | CDK1SMN1; SMN2PDE5ACDK2PDE4A | |
| SCHEMBL20119680 | 0.83 | TMIGD3 (0.45) | TMIGD3HTR2CHTR2BCDK1SMN1; SMN2 | |
| SCHEMBL6780917 | 0.83 | CDK1 (0.48) | TMIGD3HTR2CHTR2BCDK1PDE5A | |
| SCHEMBL20119693 | 0.83 | KCNH3 (0.40) | TMIGD3HTR2CHTR2BCDK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12023338-B2 | Pharmaceutical composition and treatment method for genetic disease associated with splicing abnormalities | KYOTO UNIVERSITY (JP) | 2024-07-02 | — | — | US | disclosed |
| US-12023338-B2 | Pharmaceutical composition and treatment method for genetic disease associated with splicing abnormalities | KYOTO UNIVERSITY (JP) | 2024-07-02 | — | — | US | disclosed |
| US-20230279007-A1 | Compounds for Improving mRNA Splicing | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2023-09-07 | — | — | US | disclosed |
| US-20230279007-A1 | Compounds for Improving mRNA Splicing | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2023-09-07 | — | — | US | disclosed |
| US-11702417-B2 | Compounds for improving mRNA splicing | THE GENERAL HOSPITAL CORPORATION (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702417-B2 | Compounds for improving mRNA splicing | THE GENERAL HOSPITAL CORPORATION (US) | 2023-07-18 | — | — | US | disclosed |
| US-20210205314-A1 | PHARMACEUTICAL COMPOSITION AND TREATMENT METHOD FOR GENETIC DISEASE ASSOCIATED WITH SPLICING ABNORMALITIES | KYOTO UNIVERSITY (JP) | 2021-07-08 | — | — | US | disclosed |
| US-20200283441-A1 | Compounds for Improving mRNA Splicing | THE GENERAL HOSPITAL CORPORATION | 2020-09-10 | — | — | US | disclosed |
| US-10676475-B2 | Compounds for improving mRNA splicing | THE GENERAL HOSPITAL CORPORATION (US) | 2020-06-09 | — | — | US | disclosed |
| US-20200113907-A1 | PHARMACEUTICAL COMPOSITION AND TREATMENT METHOD FOR GENETIC DISEASE ASSOCIATED WITH SPLICING ABNORMALITIES | KYOTO UNIVERSITY (JP) | 2020-04-16 | — | — | US | disclosed |
| US-20180118748-A1 | Compounds for Improving mRNA Splicing | THE GENERAL HOSPITAL CORPORATION | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230279007-A1 | Compounds for Improving mRNA Splicing | RTCB, RBM17, HNRNPA2B1 | TMIGD3 3572/4885HTR2C 3918/4885HTR2B 3882/4885 |
| US-20210205314-A1 | PHARMACEUTICAL COMPOSITION AND TREATMENT METHOD FOR GENETIC DISEASE ASSOCIATED WITH SPLICING ABNORMALITIES | RBM17, SFPQ, HNRNPAB | TMIGD3 3036/4885HTR2C 4435/4885HTR2B 4337/4885 |
| US-12023338-B2 | Pharmaceutical composition and treatment method for genetic disease associated with splicing abnormalities | RBM17, SFPQ, HNRNPAB | TMIGD3 3036/4885HTR2C 4435/4885HTR2B 4337/4885 |
| US-10676475-B2 | Compounds for improving mRNA splicing | RTCB, RBM17, HNRNPA2B1 | TMIGD3 3572/4885HTR2C 3918/4885HTR2B 3882/4885 |
| US-20180118748-A1 | Compounds for Improving mRNA Splicing | RTCB, RBM17, HNRNPA2B1 | TMIGD3 3572/4885HTR2C 3918/4885HTR2B 3882/4885 |
| US-11702417-B2 | Compounds for improving mRNA splicing | RTCB, RBM17, HNRNPA2B1 | TMIGD3 3572/4885HTR2C 3918/4885HTR2B 3882/4885 |
| US-20200113907-A1 | PHARMACEUTICAL COMPOSITION AND TREATMENT METHOD FOR GENETIC DISEASE ASSOCIATED WITH SPLICING ABNORMALITIES | RBM17, SFPQ, HNRNPAB | TMIGD3 3036/4885HTR2C 4435/4885HTR2B 4337/4885 |
| US-20200283441-A1 | Compounds for Improving mRNA Splicing | RTCB, RBM17, HNRNPA2B1 | TMIGD3 3572/4885HTR2C 3918/4885HTR2B 3882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.